Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.XTL stops drug development after study results
The trial evaluated the safety, tolerability and antiviral activity of single and multiple doses of the drug, XTL-2125, with 56 patients. Although XTL-2125 was generally well tolerated, the
The trial evaluated the safety, tolerability and antiviral activity of single and multiple doses of the drug, XTL-2125, with 56 patients. Although XTL-2125 was generally well tolerated, the
The project, involving the University College of London, Moorfields Eye Hospital and the University of Sheffield, will involve producing a cell replacement therapy from human embryonic stem cells.
Out of 30 patients evaluable for efficacy, nine (30%) showed evidence of clinical benefit with duration of response ranging from 9.4 to 26.5 months. Progression free survival was
The randomized, double-blind study is enrolling approximately 510 secondary progressive MS patients at approximately 60 sites across the US who will be administered either the peptide, MBP8298, or
The results from the phase II trial for its investigational MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) in MAGE-A3 positive patients with stage IB or II non-small cell lung cancer
The $16.3 million acquisition will expand Enzo’s life sciences product development, production and marketing capabilities, the company said. Axxora will become a wholly-owned subsidiary of New York-based Enzo.
The trial, studying the company’s selective electrochemical tumor ablation (SECTA) treatment has been halted on the advice of the independent data monitoring committee (DMC). The committee expressed concern
Cyclosporine, marketed as Neoral, is an immunosuppressant developed by Novartis for the prevention of organ rejection following kidney, liver or heart transplantation. In late 2004, Chiron Corporation (now
Terms of the transaction were not disclosed. Additionally, the sale includes the divestiture of the California-based company’s product Reptilase. Timothy Tyson, Valeant’s president and CEO, said: “The sale
GSK has started a registration bioequivalence study for the new formulation – an orally disintegrating tablet formulation of an undisclosed compound – triggering the payment. “We are delighted